WilmerHale Represents Underwriters in Graybug Vision’s Initial Public Offering

WilmerHale Represents Underwriters in Graybug Vision’s Initial Public Offering

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in connection with the $90 million initial public offering of Graybug Vision, Inc., a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic diseases of the retina and optic nerve. Graybug Vision’s shares began trading on the Nasdaq Global Market on September 25, 2020.

The WilmerHale team included partners Lisa Firenze and Chris Barnstable-Brown, counsel Craig Hilts, senior associate Hilary-Baker Jennings and associate Lugar Choi on corporate and capital markets matters, with support from Bruce Manheim, Colleen Superko and Heidi Treiber.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel